Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 20/20 | 0.57 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4405572 | 0.91 | F2R (0.55) | F2RF2 | |
| SCHEMBL13594345 | 0.87 | F2R (0.54) | F2RF2 | |
| SCHEMBL13594560 | 0.81 | F2R (0.50) | F2R | |
| SCHEMBL13594357 | 0.81 | F2R (0.50) | F2R | |
| SCHEMBL13594343 | 0.79 | F2R (0.45) | F2R | |
| SCHEMBL13594351 | 0.78 | F2R (0.51) | F2RF2 | |
| SCHEMBL4399845 | 0.77 | CACNB4 (0.54) | F2RF2 | |
| SCHEMBL8495526 | 0.76 | CTSL (0.54) | F2 | |
| SCHEMBL8495706 | 0.76 | CTSL (0.54) | F2 | |
| SCHEMBL26429562 | 0.74 | CTSL (0.55) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629319-B2 | Heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-08 | — | — | US | disclosed |
| US-7618945-B2 | Heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-11-17 | — | — | US | disclosed |
| US-20060009396-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-12 | — | — | US | disclosed |
| US-20040138141-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009396-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | PTAFR, F2R, F2RL1 | F2R 2/4885F2 37/4885 |
| US-20040138141-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | PTAFR, F2R, F2RL1 | F2R 2/4885F2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.